Stock comparison
Alvotech
Harmony Biosciences Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | HRMY | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 67B | HRMY |
| Benjamin Graham | 51D | 60C | HRMY |
| Philip Fisher | 55C | 75B | HRMY |
| Peter Lynch | 78C | 62C | ALVO |
| Joel Greenblatt | 45D | 28F | ALVO |
| Charlie Munger | 52D | 62C | HRMY |
| Terry Smith | 43D | 67B | HRMY |
Side-by-side metrics
| Metric | ALVO | HRMY |
|---|---|---|
| Market cap | $1.04B | $1.75B |
| P/E (TTM) | 33.1x | 11.8x |
| EV/EBIT | 29.5x | 6.4x |
| ROIC (TTM) | 1.3% | 12.5% |
| Gross margin | 59.82% | 76.55% |
| Net margin | 4.76% | 16.2% |
| Revenue CAGR 5y | 99.83% | 29.85% |
| EPS CAGR 5y | - | 46.45% |
| Debt / Equity | - | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Debt / Equity-vs 0.2x+104%
- Revenue CAGR 5y99.83%vs 29.85%+70%
HRMY leads on
- ROIC (TTM)12.5%vs 1.3%+90%
- EV/EBIT6.4xvs 29.5x+78%
- Net margin16.2%vs 4.76%+71%
- P/E (TTM)11.8xvs 33.1x+64%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.